NewsRoom Articles - Page 3 of 226

TuesdayFeb 03, 2026 10:00 am

Policy Expert Offers Suggestions for Curbing US Health Care Costs

According to recent data, health expenditures in the U.S. reached $5.3 trillion in 2024. That figure equates to 18% of GDP, and is double what is spent on average in other developed countries. Americans are feeling the pinch, and an estimated 100 million individuals in the country have medical debt. This situation is unsustainable. While there is broad agreement that the health care system is in crisis, there are sharp divides on what solutions need to be implemented to fix the skyrocketing cost of health care in the U.S. Jordan Bruneau, the Great Lakes Policy Institute’s director, offers some recommendations that Americans themselves can implement without waiting for lawmakers and other…

MondayFeb 02, 2026 12:00 pm

Soligenix Inc. (NASDAQ: SNGX) Builds Momentum in Fight Against Rare, Chronic Cancer

Although CTCL may progress slowly in its early stages, it remains a chronic and ultimately progressive disease for many patients. Front-line therapies for CTCL remain limited and fragmented. Soligenix is advancing a distinct approach to CTCL treatment through the development of HyBryte(TM), also known as SGX301 or synthetic hypericin. Cutaneous T-cell lymphoma (“CTCL”) remains a cancer with limited treatment options, persistent symptoms and long-term quality-of-life challenges for patients, even decades after its classification as a distinct disease. Despite medical advances in oncology, many people living with CTCL continue to cycle through therapies that offer only partial relief or introduce new…

FridayJan 30, 2026 10:30 am

Soligenix (NASDAQ: SNGX) Positioning for Impact in Growing Rare-Disease Landscape

The World Health Organization’s recent recognition of rare diseases as a global health priority underscores their collective impact. Soligenix remains focused on delivering meaningful progress in rare disease-based therapeutics and public health. In its Specialized Biotherapeutics segment, Soligenix is advancing candidates designed for orphan diseases and other serious conditions where treatment options are limited. As the global burden of rare diseases continues to rise, there is increasing urgency for innovative therapies that address unmet medical needs. More than 300 million people worldwide live with one or more rare diseases, many of which have limited or no approved treatment options, and…

FridayJan 30, 2026 10:00 am

New Compound Could Become a Transformational Brain Cancer Pill

Researchers at the University of Chicago have identified a compound that has shown efficacy in shrinking tumors in the brains of mice. This has created hope that the compound could, in future, be made into a pill that can treat glioblastoma, one of the deadliest forms of brain cancer. Hui Li, PhD, who led the study team, explains that compound A, as the substance is known, attached to a target on glioblastoma that hadn’t been known to serve as a therapeutic target. The researchers used mouse models in their study and they are now working to develop variants of compound A that are suitable for use in clinical trials. So far, 160 versions of this molecule…

ThursdayJan 29, 2026 10:00 am

Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds

Scientists have found that keeping circadian rhythms, the variations in body processes during the course of the day, in mind while administering immunotherapy could hold the key to boosting treatment outcomes in patients with cancer. The study, which was conducted by teams based at Zhujiang Hospital, Donghai County People’s Hospital and many other national research centers in China, involved conducting an integrated review of recent scientific studies on how circadian rhythms influence the microenvironment within tumors and in turn play a role in the outcomes of immunotherapy treatments, especially therapies aimed at blocking immune checkpoints. Immunotherapy has transformed cancer care in recent years, but the treatment’s effectiveness varies widely for…

ThursdayJan 29, 2026 9:45 am

The 47% Signal: Why Earth Science Tech Inc.’s (ETST) Management Is Betting the House on ETST

While many capitalization structures are diluted in the landscape of over-the-counter (“OTC”) markets, Earth Science Tech is doing the opposite, as the management team owns over 47% of the shares This high level of insider ownership is significant, as it shows the leadership strongly believes in the company, and have financial outcomes tied closely to the stock’s performance As a result, this greatly reduces the risk that management benefits while investors don’t, as management is financially aligned with outside investors In many over-the-counter (“OTC”) markets, capitalization structures are often diluted, and the incentives of management are misaligned, which may leave…

TuesdayJan 27, 2026 10:00 am

The US Formally Exits the World Health Organization

The United States has formally communicated its immediate withdrawal from the World Health Organization (WHO), denying the global body one of its largest donors. The withdrawal follows the signing of an executive order to this effect during the first months of Trump’s current administration. Trump based his decision to withdraw from the body on his strong criticism of the WHO as being excessively “China-centric” during the time when the world was paralyzed by the Covid-19 pandemic. The U.S. Health & Human Services department revealed that this withdrawal decision was taken because the World Health Organization mishandled the pandemic, was unable to reform, and…

FridayJan 23, 2026 10:00 am

Meta Analysis Finds That Weight Reduction Reduces Severity of Psoriasis

Psoriasis is a chronic skin condition that afflicts at least 60 million individuals globally. Nearly 80% of these affected people also tend to be either overweight or obese. Excess weight has been a known risk factor for psoriasis development, but until now, no rigorous scientific data existed on how the quality of life of patients and the disease severity are impacted when interventions to reduce weight are instituted for psoriatic patients. Now a meta-analysis and systematic review conducted in the UK has established that patients with psoriasis register notable improvements in their quality of life and the severity of the condition reduces when these patients undertake either lifestyle or pharmacological measures aimed at reducing…

ThursdayJan 22, 2026 10:00 am

New Digital Twin Predicts Outcomes of Brain Cancer Treatments

Researchers at the University of Michigan (U-M) have developed a system that leverages both AI and machine learning to create a digital twin of a patient’s brain cancer in order to predict how that patient will respond to different treatments. This tool promises to take personalized cancer care a step higher. The study, whose findings appeared in the journal Cell Metabolism, focused on gliomas. The team sought to establish how to distinguish between patients that are likely to benefit when their diets exclude certain amino acids (proteins) and those who are unlikely to benefit from such dietary changes. Some gliomas starve when these nutrients aren’t available in the food that a patient consumes, but some gliomas can “scavenge” for…

ThursdayJan 22, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Advances a Novel Approach to Enhancing Cancer Therapy

LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile The company is building a differentiated oncology pipeline supported by experienced leadership and scientific expertise LIXTE Biotechnology (NASDAQ: LIXT) is a clinical-stage pharmaceutical company leading efforts in addressing some of the pressing challenges in cancer treatment. Instead of developing standalone cancer drugs, the company is adopting a different strategy aimed at enhancing the overall effectiveness of existing immunotherapy and chemotherapy regimens through a novel biological target. LIXTE’s…